| BioLok International Expands National Sales Coverage |
|
|
|
| Wednesday, 09 November 2005 | |
BioLok International Expands National Sales CoverageDEERFIELD BEACH, FL, (NAMC) - BioLok International Inc. (OTCBB: BLLI), the manufacturer and worldwide distributor of leading-edge dental implant technology, today announced that it has expanded its national sales coverage in the US. The Company added sales managers in Orange County, CA, Atlanta, GA, Denver, CO, and Connecticut. "Based on our success to date of increasing sales and market share, we are pleased to announce the expansion of our direct sales force in the United States," said Bruce L. Hollander, President of BioLok International. "The new sales managers enable us to broaden our coverage of some of the largest markets, including California and the northeast's tri-state area. In addition, we have now entered for the first time attractive markets in Atlanta and Denver. Our plans for managed growth call for the hiring of additional sales people by the end of this calendar year and next year." BioLok International Inc. (OTCBB: BLLI) is merging cell biology and technology to develop and market products for the dental implant and tissue regeneration markets. The Company is the worldwide manufacturer and distributor of the BioLok Precision Dental Implant System. BioLok offers a superior line of dental implants that incorporate many patented features and are synonymous with quality, fit of components, leading edge technology and design, and ease of use. With funding from the National Institutes of Health (NIH) and the National Science Foundation (NSF), BioLok's research and development subsidiary, Orthogen, has developed and patented a proprietary laser microgrooving technology which has been assigned to BioLok. Subsequently, BioLok applied the technology for processing the surfaces of dental implants and related medical products to enhance tissue attachment. The product is marketed by BioLok under the trade name Laser-Lok(TM) and is the basis for significant revenue growth and market share gains by the Company. The laser microgrooving technology has potential applications for transcutaneous devices, orthopaedic implants, peripheral nerve repair, bioreactors, cardiovascular and ophthalmic devices. The Company has ongoing research programs with patents pending or issued in each of these areas. Additional information is available on the Company's Web site at www.biolok.com. With the exception of the historical information contained in the release, the matters described herein contain certain "forward-looking statements" that are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. The statements contained in this release, which are not historical facts may be deemed to contain forward-looking statements, including, but not limited to, deployment of new services, growth of the customer base, and growth of the service area, among other items. Actual results may differ materially from those anticipated in any forward-looking statement with regard to magnitude, timing or other factors. Deviation may result from risk and uncertainties, including, without limitation, the Company's dependence on third parties, market conditions for the sale of services, technical factors affecting networks, availability of capital and other risks and uncertainties. More detailed information about these risk factors are set forth and may be updated from time to time in filings by BioLok International, Inc. with the Securities and Exchange Commission, including the Company's most recent quarterly report on Form 10-Q and other publicly available information regarding the Company. The Company disclaims any obligation to update information contained in any forward-looking statement. Contact: |
